Sitravatinib is a receptor tyrosine kinase inhibitor under investigation in clinical trials, including a study of its use in combination with nivolumab for clear cell renal cell carcinoma. It is a pharmaceutical raw material used in research and manufacturing.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing Sitravatinib?
Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.
JNJ-28312141 free base
pharmaceutical raw material
Treprostinil Impurity 19
pharmaceutical raw material
Tandospirone citrate
pharmaceutical raw material
Pioglitazone hydrochloride
pharmaceutical raw material
Iturelix
pharmaceutical raw material
The international HS code for Sitravatinib (CAS 1123837-84-2) is 2934.99.
2934.99
2934 99 90
Classification per the EU customs inventory ECICS (2026-07 snapshot, HS 2022). National tariff lines and product form can affect the final classification.
1-N'-[3-fluoro-4-[2-[5-[(2-methoxyethylamino)methyl]-2-pyridinyl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
WLAVZAAODLTUSW-UHFFFAOYSA-N
COCCNCC1=CN=C(C=C1)C2=CC3=NC=CC(=C3S2)OC4=C(C=C(C=C4)NC(=O)C5(CC5)C(=O)NC6=CC=C(C=C6)F)F
Sourcing Sitravatinib?
Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.